Filippo Dragoni

3 weeks ago | biorxiv.org | Fengting Wu |Milica Moskovjlevic |Filippo Dragoni |Sahana Jayaraman

AbstractAntiretroviral therapy (ART) halts HIV-1 replication, reducing plasma virus levels to below the limit of detection, but it is not curative due to a reservoir of latently infected CD4+ T cells. In some people living with HIV-1 (PLWH), plasma HIV-1 RNA becomes persistently detectable despite optimal ART. This nonsuppressible viremia (NSV) is characterized by identical, non-evolving HIV-1 RNA variants expressed from infected CD4+ T cell clones.

Nov 28, 2024 | cell.com | Milica Moskovljevic |Filippo Dragoni |Nathan L. Board |Fengting Wu |Jun S. Lai |Hao Zhang | +10 more

Keywords HIV-1 persistence HIV-1 latent reservoir latency reversal antigenic stimulation dendritic cells CD4+ T cells cytomegalovirus Introduction Antiretroviral therapy (ART) effectively blocks viral replication, but HIV-1 persists in a small pool of latently infected resting CD4+ T cells harboring inducible, replication-competent proviruses.1,2,3 This reservoir was originally characterized with a quantitative viral outgrowth assay (QVOA) in which resting CD4+ T cells are stimulated with...

Mar 1, 2024 | biorxiv.org | Filippo Dragoni |Nathan L. Board |Fengting Wu |Milica Moskovjlevic

AbstractDespite antiretroviral therapy (ART), HIV-1 persists in latently-infected CD4+ T cells, preventing cure. Antigens drive the proliferation of infected cells, precluding latent reservoir decay. However, the relationship between antigen recognition and HIV-1 gene expression is poorly understood since most studies of latency reversal use agents that induce non-specific global T cell activation.

Sep 14, 2023 | jci.org | Filippo Dragoni |Rebecca T. Veenhuis |Abena Kwaa |Caroline C.G. Traut

Clinical MedicineAIDS/HIVOpen Access | 10.1172/JCI171097 J Clin Invest. https://doi.org/10.1172/JCI171097. Copyright © 2023, Dragoni et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. View PDF Abstract Version historyVersion1(September 12, 2023):In-Press Preview